Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Godfrey J. Quin"'
Autor:
Vuong Nguyen, Mark C Gillies, Hemal Mehta, Dania Qatarneh, Sanjeewa S. Wickremasinghe, Lyndell L Lim, Samantha Fraser-Bell, Lauren A.B. Hodgson, Godfrey J. Quin, Ian L. McAllister
Publikováno v:
Ophthalmology Retina. 3:286-287
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f173c259f02d8640969ec758d3a83c56
https://doi.org/10.1016/j.oret.2018.10.010
https://doi.org/10.1016/j.oret.2018.10.010
Autor:
Pearse A. Keane, Mark C Gillies, Godfrey J. Quin, Samantha Fraser-Bell, Lyndell L Lim, Aaron Yeung, Ian L. McAllister, Anna Campain, Hemal Mehta
Publikováno v:
British Journal of Ophthalmology. 100:1000-1004
Objective To report the effect of bevacizumab versus dexamethasone on hard exudates (HEX) in diabetic macular oedema (DME). Design Post hoc analysis of 24-month data from the Randomised clinical trial of BEVacizumab OR DEXamethasone for diabetic macu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c171c1164582f19c3f232882b5672f19
https://doi.org/10.1136/bjophthalmol-2015-307797
https://doi.org/10.1136/bjophthalmol-2015-307797
Autor:
Christine Aroney, Wedad Salem, Stephanie Goodwin, Samantha Fraser-Bell, Lyndell L Lim, Godfrey J. Quin, Anna Campain, Ian L. McAllister, Mark C Gillies, Ji Li
Publikováno v:
Ophthalmology. 121:2473-2481
Objective To report the 12-month results of the first head-to-head comparison of a dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, CA) versus bevacizumab (Avastin; Genentech, South San Francisco, CA) for center-involving diabetic macular edem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa0bafbe4a8182aa3f5296ba4d38aaba
https://doi.org/10.1016/j.ophtha.2014.07.002
https://doi.org/10.1016/j.ophtha.2014.07.002
Publikováno v:
Clinical & Experimental Ophthalmology. 43:180-187
Background Diabetic macular oedema (DMO) is the commonest cause of vision loss in people with diabetes. Laser photocoagulation can be effective in the treatment of DMO; however, its mechanism of action is still poorly understood. A better understandi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca2c3179d3ceb9b7f15e31c5a8895455
https://doi.org/10.1111/ceo.12372
https://doi.org/10.1111/ceo.12372
Publikováno v:
Clinical & Experimental Ophthalmology. 41:187-200
Most acute cases of central serous chorioretinopathy resolve spontaneously with minimal visual impairment. The small percentage of eyes developing chronic or recurrent disease that do warrant treatment is often difficult to control. Emergent investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2f977c04e6003c473d2bbe993bc30b5
https://doi.org/10.1111/j.1442-9071.2012.02847.x
https://doi.org/10.1111/j.1442-9071.2012.02847.x
Publikováno v:
Clinical & Experimental Ophthalmology. 41:201-214
Central serous chorioretinopathy (CSCR) is a common retinal cause of vision loss. This review surveys the epidemiology, risk factors, clinical presentation, natural history and pathophysiology of CSCR. Studies suggest an annual incidence rate of 10 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce032aaf5376c5597261c33970c98d05
https://doi.org/10.1111/j.1442-9071.2012.02848.x
https://doi.org/10.1111/j.1442-9071.2012.02848.x
Autor:
Jaclyn Bryant, Mark C Gillies, Christine Aroney, Ji Li, Samantha Fraser-Bell, Godfrey J. Quin, Anna Campain, Ian L. McAllister, Lyndell L Lim, Hemal Mehta
Publikováno v:
Ophthalmology. 123(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3720c018237b3e0e54a2a70d2312401
https://pubmed.ncbi.nlm.nih.gov/26783096
https://pubmed.ncbi.nlm.nih.gov/26783096
Autor:
Mark C, Gillies, Lyndell L, Lim, Anna, Campain, Godfrey J, Quin, Wedad, Salem, Ji, Li, Stephanie, Goodwin, Christine, Aroney, Ian L, McAllister, Samantha, Fraser-Bell
Publikováno v:
Ophthalmology. 121(12)
To report the 12-month results of the first head-to-head comparison of a dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, CA) versus bevacizumab (Avastin; Genentech, South San Francisco, CA) for center-involving diabetic macular edema (DME).Ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::615a71d477f5b214db25189cce2ef68f
https://pubmed.ncbi.nlm.nih.gov/25155371
https://pubmed.ncbi.nlm.nih.gov/25155371
Publikováno v:
Clinicalexperimental ophthalmology. 43(2)
Diabetic macular oedema (DMO) is the commonest cause of vision loss in people with diabetes. Laser photocoagulation can be effective in the treatment of DMO; however, its mechanism of action is still poorly understood. A better understanding of these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::29429b3a2188aaeb9f91c92bfd60e339
https://pubmed.ncbi.nlm.nih.gov/24978816
https://pubmed.ncbi.nlm.nih.gov/24978816
Publikováno v:
Proteomics. 7(15)
We have employed proteomics to establish a proteome map of the normal rat retina. This baseline map was then used for comparison with the early diabetic rat retinal proteome. Diabetic rat retinae were obtained from Dark Agouti rats after 10 wk of str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33028042d06decf40be4569fc7855d1
https://pubmed.ncbi.nlm.nih.gov/17647246
https://pubmed.ncbi.nlm.nih.gov/17647246